Sonoma Pharmaceuticals (SNOA) Interest Expenses (2010 - 2026)

Sonoma Pharmaceuticals' Interest Expenses history runs 17 years deep, the most recent figure standing at -$4000.0 for Q1 2026.

• On a quarterly basis, Interest Expenses fell 233.33% year-over-year to -$4000.0 in Q1 2026; TTM through Mar 2026 was $6000.0, a 60.0% decrease from a year earlier, with the FY2026 full-year figure at $26.6 million, down 8.64% from the prior year.
• Interest Expenses declined to -$4000.0 in Q1 2026 per SNOA's latest filing, from $12000.0 in the prior quarter.
• Across five years, Interest Expenses topped out at $536000.0 in Q2 2022 and bottomed at -$4000.0 in Q1 2026.
• The 5-year median for Interest Expenses is $38000.0 (2023), against an average of $139937.5.
• Across the five-year window, Interest Expenses jumped 3714.29% in 2022 and sank 233.33% in 2026, its largest moves.
• Year by year, Interest Expenses stood at $534000.0 in 2022, then tumbled by 93.63% to $34000.0 in 2023, then jumped by 420.59% to $177000.0 in 2024, then plunged by 93.22% to $12000.0 in 2025, then plunged by 133.33% to -$4000.0 in 2026.
• Per Business Quant, the three latest SNOA Interest Expenses figures stand at -$4000.0 (Q1 2026), $12000.0 (Q4 2025), and $130000.0 (Q3 2025).